levodopa has been researched along with Blepharoptosis in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (50.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdul Halim, S; Mohd Amin, NA | 1 |
| Caetano, A; Meira, B; Pinto, M; Roque, R | 1 |
| Goshima, Y; Koga, M; Masukawa, D; Ueda, S | 1 |
| Barak, LS; Beaulieu, JM; Caron, MG; Gainetdinov, RR; Sotnikova, TD; Wetsel, WC | 1 |
| Balsara, JJ; Chandorkar, AG; Gada, VP; Nandal, NV | 1 |
| Malone, MH; Namba, MM; Quock, RM | 1 |
| Fujiwara, M; Inoue, K; Ueki, S | 1 |
| el-Sawaf, HA; Puri, VN; Rao, KV | 1 |
| Maj, J; Michaluk, J; Rawłów, A; Rogóz, Z; Skuza, G | 1 |
| Bartholini, G; Bigler, R; Brossi, A; Burns, JJ; Kaiser, A; Pletscher, A; Pool, W; Sheppard, H | 1 |
10 other study(ies) available for levodopa and Blepharoptosis
| Article | Year |
|---|---|
Treatment response in osmotic demyelination syndrome presenting as severe parkinsonism, ptosis and gaze palsy.
Topics: Blepharoptosis; Diagnosis, Differential; Humans; Hyponatremia; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Myelinolysis, Central Pontine; Parkinsonian Disorders; Syndrome | 2018 |
Late-onset presentation of POLG1-associated mitochondrial disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Blepharoptosis; Disease Progression; DNA Polymerase gamma; Humans; Levodopa; Male; Mitochondrial Diseases; Ophthalmoplegia, Chronic Progressive External; Parkinsonian Disorders; Point Mutation; Treatment Outcome | 2019 |
l-3,4-Dihydroxyphenylalanine induces ptosis through a GPR143-independent mechanism in mice.
Topics: Animals; Behavior, Animal; Blepharoptosis; Eye Proteins; Levodopa; Male; Membrane Glycoproteins; Mice, Inbred C57BL; Mice, Knockout; Receptors, G-Protein-Coupled | 2016 |
Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.
Topics: alpha-Methyltyrosine; Amphetamines; Animals; Antiparkinson Agents; Basal Ganglia; Blepharoptosis; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Female; Levodopa; Male; Mice; Motor Activity; Nomifensine; Norepinephrine; Parkinson Disease, Secondary; Phenotype; Piperazines; Tyrosine 3-Monooxygenase | 2005 |
Psychopharmacological investigation of the monoamine oxidase inhibitory activity of molindone, a dihydroindolone neuroleptic.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Behavior, Animal; Blepharoptosis; Catalepsy; Fenclonine; Fenfluramine; Humans; Indoles; Levodopa; Male; Mice; Molindone; Monoamine Oxidase Inhibitors; p-Chloroamphetamine; Rats; Reserpine; Stereotyped Behavior; Tryptamines; Tryptophan | 1984 |
Effects of narcotic antagonists on L-dopa reversal of reserpine-induced catalepsy and blepharoptosis in mice.
Topics: Animals; Blepharoptosis; Catalepsy; Drug Antagonism; Drug Synergism; Humans; Kinetics; Levodopa; Male; Mice; Naloxone; Naltrexone; Reserpine | 1981 |
[Behavioral pharmacology of a new antidepressant, lopramine].
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Apomorphine; Avoidance Learning; Blepharoptosis; Body Temperature; Catalepsy; Dibenzazepines; Drug Synergism; Emotions; Humans; Imipramine; Lethal Dose 50; Levodopa; Male; Methamphetamine; Mice; Motor Activity; Muscle Relaxation; Oxotremorine; Physostigmine; Rats; Stereotyped Behavior | 1976 |
Further studies on the neuroleptic profile of manassantin A.
Topics: Adenylyl Cyclase Inhibitors; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Binding, Competitive; Blepharoptosis; Body Temperature; Catalepsy; Furans; Haloperidol; In Vitro Techniques; Levodopa; Lignans; Male; Mice; Norepinephrine; Pentobarbital; Physostigmine; Plants, Medicinal; Stereotyped Behavior | 1990 |
Central action of the antidepressant drug pirlindole.
Topics: 5-Hydroxytryptophan; Animals; Antidepressive Agents; Blepharoptosis; Body Temperature; Carbazoles; Cerebral Cortex; Clonidine; Dihydroalprenolol; Levodopa; Male; Mice; Norepinephrine; Prazosin; Rats; Reserpine; Serotonin | 1986 |
L-DOPA: chemical modifications and biological evaluation.
Topics: Animals; Antiparkinson Agents; Blepharoptosis; Catatonia; Disease Models, Animal; Humans; Hypothermia; Levodopa; Male; Mice; Oxotremorine; Parkinson Disease; Reserpine; Structure-Activity Relationship; Tremor | 1974 |